Chitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC). Obesity paradox in non-small cell lung cancer (NSCLC) patients on immune ...

Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy. Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

In February 2004, pemetrexed disodium (Alimta; Eli Lilly), an anticancer drug that targets folate-dependent reactions that are essential for cell proliferation, became the first drug to be ...

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

Daiichi Sankyo & Merck voluntarily withdraws patritumab deruxtecan BLA to treat locally advanced or metastatic EGFR-mutated NSCLC from US FDA: Basking Ridge, New Jersey Friday, Ma ...